
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is poised for significant growth driven by strategic Medicare expansions and additional coverage wins in the NIT segment, which are expected to expand the number of covered lives and provide upside potential. The company has a strong product pipeline, highlighted by the improved G7 continuous glucose monitoring systems, which are fostering increased adoption and usage among diabetic patients. Furthermore, the anticipated operational leverage and gross margin expansion from transitioning to 15-day sensors support a forecast of mid-teens revenue growth and over 20% EPS growth through 2028.
Bears say
DexCom reported sensor revenue of $1.18 billion, reflecting a year-over-year growth of 20%, but hardware revenue fell significantly by 31%, underscoring a potential weakness in product demand. Furthermore, the company's guidance for fiscal year 2026 suggests a revenue range of $5.16 billion to $5.25 billion, which is slightly below consensus expectations, indicating a trend of decelerating sales as the mix shifts towards pharmacy distribution. Amidst these financial challenges, DexCom's recent acknowledgment of a decelerating growth trend and execution issues suggests that its stock may continue to face downward pressure compared to competitors.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares